The breakthrough makes bio‑derived acrylic acid economically competitive, reducing reliance on fossil fuels and cutting greenhouse‑gas emissions across high‑volume markets like diapers and paints.
The shift toward renewable feedstocks has accelerated as petrochemical costs rise and climate regulations tighten. 3‑Hydroxypropionic acid (3‑HP) sits at the nexus of this transition, serving as a direct precursor to acrylic acid, a cornerstone of adhesives, coatings, and absorbent polymers. Historically, microbial production of 3‑HP suffered from low yields and costly downstream processing, limiting its commercial appeal. By selecting *Issatchenkia orientalis*, a yeast naturally thriving at low pH, researchers sidestepped the neutral‑pH requirements of bacterial hosts, simplifying purification and reducing capital expenditures.
The engineering strategy combined genome‑scale modeling with a bespoke genetic toolbox to amplify the beta‑alanine pathway, integrating multiple copies of the PAND enzyme that catalyzes the final biosynthetic step. This multi‑layered approach lifted the theoretical yield to 70 % of the substrate’s carbon content and pushed product concentration to 92 g L⁻¹, benchmarks that meet and exceed thresholds identified in prior techno‑economic studies. Simulations with the BioSTEAM platform incorporated realistic fermentation cycles, feedstock costs, and energy balances, revealing a competitive internal rate of return for a plant producing bio‑based acrylic acid at scale.
Beyond the immediate economics, the technology promises broader environmental dividends. Life‑cycle assessments show a marked reduction in CO₂ emissions compared with conventional petrochemical routes, aligning with corporate sustainability targets and emerging regulatory frameworks. With a $20 billion market and growing consumer demand for greener products, the scalable yeast platform could catalyze a wave of bio‑derived chemicals, from acrylics to malonic acid derivatives. Ongoing collaborations aim to integrate alternative feedstocks and streamline downstream separation, positioning the process for rapid industrial adoption and reinforcing the United States’ leadership in bio‑manufacturing innovation.
Comments
Want to join the conversation?
Loading comments...